NCX 4215

Drug Profile

NCX 4215

Latest Information Update: 10 Nov 1998

Price : $50

At a glance

  • Originator NicOx
  • Class Antiplatelets; Benzoic acids; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 10 Nov 1998 Discontinued-Preclinical for Thrombosis in United Kingdom (Unknown route)
  • 10 Nov 1998 Discontinued-Preclinical for Thrombosis in Italy (Unknown route)
  • 14 Oct 1998 No-Development-Reported for Thrombosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top